drugset / Trial / NCT01613768
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
NaSingle-groupOpen-labelTreatment
Summary
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
Timeline
- Start
- 2012-05-08
- Primary completion
- 2017-08-23
- Completion
- 2017-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | — | Intravenous |